Open AccessP056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series
Author(s) -
Parra Izquierdo Viviana,
Frias-Ordoñez Juan,
Pablo Galindo,
Romero-Sánchez Consuelo,
Cristian Flórez
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000798824.75637.a6
Subject(s) - medicine , tofacitinib , ulcerative colitis , golimumab , infliximab , adalimumab , gastroenterology , janus kinase inhibitor , adverse effect , pancolitis , inflammatory bowel disease , colectomy , surgery , rheumatoid arthritis , colonoscopy , disease , colorectal cancer , cancer
Tofacitinib is a molecule that inhibits Janus kinases, enzymes involved ulcerative colitis (UC) pathogenesis. This drug has recently been approved by INVIMA (abbreviation in Spanish of National Institute of Food and Drug Surveillance) in Colombia.